Covaxin has drawn global attention: ICMR

New Delhi: Indian vaccine against COVID-19, Covaxin, has drawn global attention, according to Indian Council of Medical Research (ICMR).

The ICMR in a tweet said: “India’s indigenous vaccine against COVID19 Covaxin-a product of ICMR-Bharat Biotech collaboration, achieves the remarkable feat. Data generated from within India underlines impressive safety and immunogenicity profile of Covaxin and sparks Lancet’s interest in publishing them.”

The encouraging Phase I and Phase II COVAXIN trial have resulted paving the way for Phase III Clinical Trial in India. The trial is presently going on at 22 sites, the ICMR said.

Meanwhile, AIIMS, New Delhi, has invited volunteers for the Phase III clinical trial of the indigenously developed COVID-19 vaccine candidate ‘Covaxin’ for which it is one of the sites.

Dr Sanjay K Rai, AIIMS Centre for Community Medicine, said that the Phase I/II trials (safety and immunogenicity) have already been completed.

Breaking